Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

August 24, 2005

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Lymphoma
Interventions
DRUG

carmustine

Day -6, 300 mg/m\^2 over 2 hour

DRUG

cyclophosphamide

"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."

DRUG

etoposide

"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m\^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."

PROCEDURE

peripheral blood stem cell transplantation

Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.

RADIATION

irradiation therapy

"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain."

BIOLOGICAL

G-CSF

"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF."

DRUG

Cytarabine

100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.

Trial Locations (1)

55455

Masonic Cancer Center at University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00345865 - Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter